2009
DOI: 10.1016/j.bmcl.2009.03.165
|View full text |Cite
|
Sign up to set email alerts
|

Second generation of BACE-1 inhibitors. Part 1: The need for improved pharmacokinetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
24
0

Year Published

2010
2010
2018
2018

Publication Types

Select...
7
1
1

Relationship

0
9

Authors

Journals

citations
Cited by 47 publications
(25 citation statements)
references
References 12 publications
1
24
0
Order By: Relevance
“…Despite significant progress in understanding the molecular and cellular effects of HEAs has been done [9,[12][13][14], a few theoretical studies, to the best of our knowledge, have been reported [15][16][17][18]. More particularly, such an approach is expected to shed some light onto the role of protein-ligand interactions for this system.…”
Section: Introductionmentioning
confidence: 89%
See 1 more Smart Citation
“…Despite significant progress in understanding the molecular and cellular effects of HEAs has been done [9,[12][13][14], a few theoretical studies, to the best of our knowledge, have been reported [15][16][17][18]. More particularly, such an approach is expected to shed some light onto the role of protein-ligand interactions for this system.…”
Section: Introductionmentioning
confidence: 89%
“…Recently, it was described the first and second generation of novel hydroxyethylamines (HEAs) acting as BACE-1 inhibitors with; nanomolar potency in cells, favorable pharmacokinetic properties and orally bioavailables [6][7][8][9][10][11]. Despite significant progress in understanding the molecular and cellular effects of HEAs has been done [9,[12][13][14], a few theoretical studies, to the best of our knowledge, have been reported [15][16][17][18].…”
Section: Introductionmentioning
confidence: 94%
“…Hydrogen atoms were added to the protein utilizing DS 2.0 templates for protein residues. Gasteiger-Marsili charges were assigned to the protein atoms as implemented within DS 2.5 [33,34]. The protein structures were utilized in subsequent docking experiments without energy minimization.…”
Section: S12 Preparation Of Crystal Structuresmentioning
confidence: 99%
“…These plaques consist of aggregated amyloid--peptide (A ) deposits, -protein aggregation, oxidative stress, dyshomeostasis of biometals, and low acetylcholine (ACh) levels and plays significant role in the pathophysiology of the disease [7]. Nowadays, the most used therapeutic treatment against AD involves the use of acetylcholinesterase inhibitors (AChEIs) that improve AD symptoms by AChE inhibition [8][9][10][11][12]. The reversible AChE inhibition has become the promising target for the treatment of AD which is mainly associated with low in vivo AChE levels.…”
Section: Introductionmentioning
confidence: 99%